Comorbidities as Risk Factors for Acute and Recurrent Erysipelas.
Erysipelas
Lymphoedema
Recurrent
Risk factor
Journal
Open access Macedonian journal of medical sciences
ISSN: 1857-9655
Titre abrégé: Open Access Maced J Med Sci
Pays: North Macedonia
ID NLM: 101662294
Informations de publication
Date de publication:
30 Mar 2019
30 Mar 2019
Historique:
received:
15
02
2019
revised:
12
03
2019
accepted:
13
03
2019
entrez:
13
4
2019
pubmed:
13
4
2019
medline:
13
4
2019
Statut:
epublish
Résumé
Erysipelas is a common infectious skin disease. A typical feature of erysipelas, especially on the lower limbs, is the tendency to reoccur and the study aimed to define the comorbidities associated with it. We aimed to investigate systemic and local comorbidities in patients diagnosed with erysipelas on the lower limbs. We conducted a retrospectively-prospective, population-based cohort study which included all patients diagnosed with erysipelas on the lower limbs, during two years. Patients were divided into two groups: patients with first episode and patients with recurrent erysipelas. These two groups were compared, with particular emphasis on systemic and local comorbidities. The study included 313 patients, of which 187 with the first episode of erysipelas and 126 with a recurrent. Regarding the analyzed systemic risk factors, the recurrent erysipelas was significantly associated with obesity (p < 0.0001), insulin dependent diabetes mellitus (p = 0.0015), history of malignant disease (p = 0.02) and tonsillectomy (p = 0.000001). For a p-value < 0.0001, significantly more frequent finding of peripheral arterial occlusive disease, chronic oedema/lymphoedema, fungal infections of the affected leg and chronic ulcer was confirmed in recurrent erysipelas. Neuropathy had 23% of the recurrent cases and 8.6% in patients without recurrence, and the difference was found to be significant for p = 0.0003. The only dissection of the lymph nodes was found more frequently in recurrent erysipelas (p = 0.017), but no associations with other analysed local surgery on the affected leg. Patients with recurrent erysipelas had ipsilateral coexisting dermatitis p = 0.00003 significantly more frequent. Minor trauma often preceded the first episode of erysipelas p = 0.005. Identification and treatment of modifiable risk factors are expected to reduce the risk of a subsequent episode of erysipelas on the lower limbs.
Sections du résumé
BACKGROUND
BACKGROUND
Erysipelas is a common infectious skin disease. A typical feature of erysipelas, especially on the lower limbs, is the tendency to reoccur and the study aimed to define the comorbidities associated with it.
AIM
OBJECTIVE
We aimed to investigate systemic and local comorbidities in patients diagnosed with erysipelas on the lower limbs.
MATERIAL AND METHODS
METHODS
We conducted a retrospectively-prospective, population-based cohort study which included all patients diagnosed with erysipelas on the lower limbs, during two years. Patients were divided into two groups: patients with first episode and patients with recurrent erysipelas. These two groups were compared, with particular emphasis on systemic and local comorbidities.
RESULTS
RESULTS
The study included 313 patients, of which 187 with the first episode of erysipelas and 126 with a recurrent. Regarding the analyzed systemic risk factors, the recurrent erysipelas was significantly associated with obesity (p < 0.0001), insulin dependent diabetes mellitus (p = 0.0015), history of malignant disease (p = 0.02) and tonsillectomy (p = 0.000001). For a p-value < 0.0001, significantly more frequent finding of peripheral arterial occlusive disease, chronic oedema/lymphoedema, fungal infections of the affected leg and chronic ulcer was confirmed in recurrent erysipelas. Neuropathy had 23% of the recurrent cases and 8.6% in patients without recurrence, and the difference was found to be significant for p = 0.0003. The only dissection of the lymph nodes was found more frequently in recurrent erysipelas (p = 0.017), but no associations with other analysed local surgery on the affected leg. Patients with recurrent erysipelas had ipsilateral coexisting dermatitis p = 0.00003 significantly more frequent. Minor trauma often preceded the first episode of erysipelas p = 0.005.
CONCLUSION
CONCLUSIONS
Identification and treatment of modifiable risk factors are expected to reduce the risk of a subsequent episode of erysipelas on the lower limbs.
Identifiants
pubmed: 30976336
doi: 10.3889/oamjms.2019.214
pii: OAMJMS-7-937
pmc: PMC6454161
doi:
Types de publication
Journal Article
Langues
eng
Pagination
937-942Références
BMJ. 1999 Jun 12;318(7198):1591-4
pubmed: 10364117
Clin Infect Dis. 1999 Nov;29(5):1319-20
pubmed: 10524984
Parasitol Today. 2000 Dec;16(12):544-8
pubmed: 11121854
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
Ann Dermatol Venereol. 2001 Mar;128(3 Pt 2):463-82
pubmed: 11319379
J Surg Res. 2002 Nov;108(1):122-8
pubmed: 12443724
Emerg Infect Dis. 2003 Aug;9(8):970-7
pubmed: 12967496
JAMA. 1963 Jul 13;185:80-2
pubmed: 13989558
QJM. 2003 Oct;96(10):731-8
pubmed: 14500859
J Antimicrob Chemother. 2003 Nov;52 Suppl 1:i3-17
pubmed: 14662806
N Engl J Med. 2004 Feb 26;350(9):904-12
pubmed: 14985488
Clin Infect Dis. 2005 Nov 15;41(10):1416-22
pubmed: 16231251
J Dtsch Dermatol Ges. 2004 Feb;2(2):89-95
pubmed: 16279242
Epidemiol Infect. 2006 Apr;134(2):293-9
pubmed: 16490133
J Eur Acad Dermatol Venereol. 2006 Aug;20(7):834-9
pubmed: 16898907
Br J Dermatol. 2006 Nov;155(5):947-50
pubmed: 17034523
Am J Med Sci. 2006 Dec;332(6):304-7
pubmed: 17170620
Clin Infect Dis. 2007 Apr 15;44(8):1141-2
pubmed: 17366471
Arch Intern Med. 2007 Apr 9;167(7):709-15
pubmed: 17420430
Dermatology. 2007;215(2):118-22
pubmed: 17684373
Clin Microbiol Infect. 2010 Jun;16(6):729-34
pubmed: 19694769
J Infect. 2012 Feb;64(2):148-55
pubmed: 22101078
Eur J Clin Microbiol Infect Dis. 2013 Mar;32(3):369-72
pubmed: 23007460
N Engl J Med. 2013 May 2;368(18):1695-703
pubmed: 23635049
PLoS One. 2014 Feb 14;9(2):e82694
pubmed: 24551029
J Infect. 2014 Jul;69(1):26-34
pubmed: 24576824
Clin Infect Dis. 2014 Jul 15;59(2):e10-52
pubmed: 24973422
J Am Acad Dermatol. 2015 Jan;72(1):140-5
pubmed: 25443627
BMC Infect Dis. 2015 Sep 30;15:402
pubmed: 26424182
MBio. 2016 Apr 12;7(2):e00020-16
pubmed: 27073088
JAMA. 2016 Jul 19;316(3):325-37
pubmed: 27434444
Cochrane Database Syst Rev. 2017 Jun 20;6:CD009758
pubmed: 28631307
Infection. 1987 Mar-Apr;15(2):105-6
pubmed: 3110071
Am J Med. 1985 Aug;79(2):155-9
pubmed: 3875287
JAMA. 1984 Feb 24;251(8):1049-52
pubmed: 6607365
Diabet Med. 1994 Dec;11(10):935-41
pubmed: 7895457
N Engl J Med. 1996 Jan 25;334(4):240-5
pubmed: 8532002
Aust N Z J Surg. 1996 Mar;66(3):175-7
pubmed: 8639138
Clin Infect Dis. 1996 Nov;23(5):1091-8
pubmed: 8922808
Clin Infect Dis. 1996 Nov;23(5):1162-4
pubmed: 8922818
Diabet Med. 1997 Jan;14(1):29-34
pubmed: 9017350
Laryngoscope. 1997 May;107(5):640-7
pubmed: 9149167